Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062661 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ravi Doddapaneni und 3 weiteren Autor:innen. Beteiligte Einrichtung: McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA. Hauptthemen laut MEDLINE: Naphthoquinones, Apoptosis, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carolinas Muscular Dystrophy Research Endowment at the Atrium Health Foundation.
Abstract (Originalsprache)
The mortality rate of breast cancer remains high, despite remarkable advances in chemotherapy. Therefore, it is imperative to identify new treatment options. In the present study, we investigated whether the metabolite ribitol enhances the cytotoxic effect of shikonin against breast cancer in vitro. Here, we screened a panel of small molecules targeting energy metabolism against breast cancer. The results of the study revealed that ribitol enhances shikonin’s growth-inhibitory effects, with significant synergy. A significant (p < 0.01) increase in the percentage (56%) of apoptotic cells was detected in the combined treatment group, compared to shikonin single-treatment group (38%), respectively. The combined ribitol and shikonin treatment led to significant arrest of cell proliferation (40%) (p < 0.01) compared to untreated cells, as well as the induction of apoptosis. This was associated with upregulation of p53 (p < 0.05) and downregulation of c-Myc (p < 0.01), Bcl-xL (p < 0.001), and Mcl-1 (p < 0.05). Metabolomic analysis supports the premise that inhibition of the Warburg effect is involved in shikonin-induced cell death, which is likely further enhanced by dysregulation of glycolysis and the tricarboxylic acid (TCA) cycle, afflicted by ribitol treatment. In conclusion, the present study demonstrates that the metabolite ribitol selectively enhances the cytotoxic effect mediated by shikonin against breast cancer in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA.
ORCID-Profile: Jason D Tucker
Förderung
- Carolinas Muscular Dystrophy Research Endowment at the Atrium Health Foundation
Zitieren
APA
Doddapaneni, R., Tucker, J. D., Lu, P. J., & Lu, Q. L. (2025). Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062661
Vancouver
Doddapaneni R, Tucker JD, Lu PJ, Lu QL. Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062661
BibTeX
@article{Doddapaneni2025,
author = {Doddapaneni, Ravi and Tucker, Jason D and Lu, Pei J and Lu, Qi L},
title = {Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062661}
}
EUVIMED